Wednesday 25 Jun, 2025 06:42 PM
Site map | Locate Us | Login
   Nifty June futures trade at premium    Reliance Infra hits the roof after bagging Rs 600-cr export order from Rheinmetall    Exicom Tele-Systems jumps on fundraise plan, loan-to-equity conversion in EV subsidiary    Garden Reach Shipbuilders & Engineers Ltd leads losers in 'A' group    Adani Total Gas gains on joining hands with Jio-bp to enhance auto fuel retail experience in India    Digitide Solutions Ltd leads losers in 'B' group    Volumes spurt at Network 18 Media & Investments Ltd counter    Lupin receives USFDA approval for generic Prucalopride tablets    Radico Khaitan Ltd gains for third straight session    Acme Solar's subsidiary signs 25-year PPA with SECI for 300 MW at Rs 3.05/kWh    Aurobindo Pharma gets UK MHRA approval for neutropenia treatment drug Dyrupeg    D B Corp Ltd spurts 1.36%, rises for fifth straight session    JB Chemicals receives USFDA approval for Amitriptyline Hydrochloride tablets    Global Vectra Helicorp Ltd leads gainers in 'B' group    Mahanagar Telephone Nigam Ltd leads gainers in 'A' group 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
NSE SME Influx Healthtech makes a strong debut
25-Jun-25   11:42 Hrs IST

The scrip was listed at Rs 132.50, a premium of 38.02% compared with the initial public offer (IPO) price. The stock was currently down 1.9% over its listing price.

The counter hit a high of Rs 135.85 and a low of Rs 125.90. About 28.55 lakh shares of the company changed hands at the counter.

Influx Healthtech's IPO was subscribed 187.31 times. The issue opened for bidding on 18 June 2025 and it closed on 20 June 2025. The price band of the IPO was fixed at Rs 91 to Rs 96 per share.

The IPO of 61,00,800 equity shares comprised a fresh issue of 50,00,400 equity shares and offer for sale (OFS) of 11,00,400 equity shares. The promoter and promoter group shareholding diluted to 73.53% from 99.85% pre-issue.

The company intends to utilize the net proceeds for funding capital expenditure requirements for setting up of manufacturing facility for nutraceutical division, funding capital expenditure requirements for setting up of manufacturing facility for veterinary food division, purchase of machineries for homecare and cosmetic division and general corporate expenses.

Ahead of the Influx Healthtech on 17 June 2025, raised Rs 16.66 crore from anchor investors. The board has allotted 17.36 lakh shares at Rs 96 per share to 8 anchor investors.

Influx Healthtech is a Mumbai-based, healthcare focused company specialising in contract manufacturing. Since its inception in 2020, the company has established itself as a reliable contract development and manufacturing organization (CDMO). The company offers comprehensive production services across a wide range of categories, including dietary and nutritional supplements, cosmetics, ayurvedic and herbal products, veterinary feed supplements, homecare products, active pharmaceutical ingredients (APIs), and finished dosage forms such as tablets, capsules and injectables. The company had a total workforce of 163 permanent employees on a payroll basis.

The company recorded revenue from operations of Rs 104.85 crore and net profit of Rs 13.37 crore for the period ended 31 March 2025.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Hit Count : 42199676
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL Securities Private Limited